atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
The Food and Drug Administration approved a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), an ultra-rare disease that leaves children vulnerable to life-threatening infections.
Read more here.
OpenAI launched ChatGPT Health and Anthropic added medical toolsets for Claude, meaning users can sync their records and wearables, using their personal health data to get hyper-specific answers to their medical questions. At the same time, the FDA issued new guidance…
Attendees
Sponsors and Exhibitors
Contact us